1991 Volume 39 Issue Supplement4 Pages 245-249
We evaluated the clinical efficacy and safety of sparfloxacin in a total of nine patients with respiratory tract infections; 6 with bronchiectasis and 3 with diffuse panbronchiolitis. Sparfloxacin was administered orally at a daily dose of 200 or 300mg, once or two divided doses. The time course of the serum and sputum concentrations was evaluated after administering a single dose of 300mg to two patients with copious mucopurulent sputum, and pharmacokinetic analysis was also performed.
The clinical response to the drug was rated as excellent in two cases, good in 5 and fair in one of the 8 evaluable cases, the efficacy rate being 88%. The clinical efficacy on the clinically isolated organisms was excellent in two cases with Haemophilus influenzae, good in two cases with Branhamella catarrhalis, good in one case each with Pseudomonas aeruginosa and glucosenonfermenting Gram-negative rod, and fair in one case with Streptococcus pneumoniae. No adverse reaction was observed except for one case with slight eosinophilia.
The peak concentrations in both the serum and sputum were observed at the same time in the two cases after a single administration of 300mg. The Cmax of the sputum was 5.09μg/ml and 3.55μg/ml which compares to the serum concentration as 172 and 204%, respectively. On the third and ninth day of administering 300mg of sparfloxacin in one patient, the average concentrations before and 4 hrs after administration were 0.97μg/ml and 4.68μg/ml in the sputum, and 0.88μg/ml and 3.01μg/ml in the serum, respectively.
Good penetration of sparfloxacin into the sputum suggested the high therapeutic efficacy in respiratory infections.
